Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02519348 · ClinicalTrials.gov registry record · Phase 2

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

A Phase 2 study of Hepatocellular Carcinoma, sponsored by MedImmune.

Active
Registry status
Phase 2
Development phase
433
Enrollment target
20
Study locations

NCT02519348 is a Phase 2 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 433 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (70% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02519348, a Phase 2 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by MedImmune.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
433 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • BIOLOGICAL Durvalumab
  • BIOLOGICAL Bevacizumab
  • BIOLOGICAL Tremelimumab

Study Locations (20)

Other

  • Research Site - Hangzhou
  • Research Site - Nanjing
  • Research Site - Shanghai
  • Research Site - Hong Kong

Florida

  • Research Site - Jacksonville
  • Research Site - Tampa

New York

  • Research Site - New York
  • Research Site - Stony Brook

Pennsylvania

  • Research Site - Philadelphia
  • Research Site - Philadelphia

Arizona

  • Research Site - Phoenix

California

  • Research Site - San Francisco

Connecticut

  • Research Site - New Haven

Indiana

  • Research Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 433 participants
Start Date 2015-10-19
Est. Completion 2026-04-01
Phase Phase 2

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02519348

The ClinicalTrials.gov registry entry for NCT02519348 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 433 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (70% higher). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.

NCT02519348 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT02519348 about?

NCT02519348 is a clinical study titled "A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma". This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepato...

What is the current status of trial NCT02519348?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 433 participants. The study started on 2015-10-19. Estimated completion is 2026-04-01.

What conditions does trial NCT02519348 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT02519348?

The interventions under investigation include: Durvalumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL), Tremelimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02519348?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02519348 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.